单位：[1]Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan[2]Division of Gastroenterology and Hepatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[3]Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan[4]Department Head Gastroenterology and Hepatology, Nepean Hospital, Derby Street, Kingswood, NSW, Australia[5]Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院[6]Bombay Hospital and Medical Research Centre, Mumbai, India[7]Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea[8]Department of Gastroenterology, Ziauddin University Hospital Clifton, Karachi, Pakistan[9]Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines[10]Liver Research Center, Chang Gung Memorial Hospital, Kuei Shan, Taoyuan, Taiwan中山大学附属第二医院[11]Department of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan[12]Department of Gastroenterology, Batman State Hospital, Batman, Turkey[13]Department of Gastroenterology, Numune Education and Research Hospital, Ankara, Turkey[14]Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan[15]Head of Education and Development, PBC Foundation, Edinburgh, UK[16]Department of Internal Medicine, Sanno Medical Center, Tokyo, Japan[17]Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea[18]Departments of Medicine and Surgery, Baylor College of Medicine, Houston, TX, USA
During the 25th annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL 2016) in Tokyo, we organized and moderated an inaugural satellite symposium on the autoimmune liver diseases, autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). Following the keynote lecture by John M. Vierling (USA), speakers from the Asia-Pacific region provided an up-to-date perspective on the epidemiology, clinical practice and research in AIH and PBC in the Asia-Pacific region. Although epidemiology and clinical features of AIH seem to be similar in East Asia compared to those in western countries, the majority of patients with AIH are detected at an advanced stage and have higher mortality rates in South Asia, indicating an unmet need for earlier diagnosis and the initiation of appropriate immunosuppressive treatment. PBC is more commonly seen in Australia and East Asia. As of 2016, clinical practice guidelines (CPG) for PBC have been published in Japan and China. Ursodeoxycholic acid (UDCA) is recommended as a first-line therapy by both CPG. Nevertheless, one of the unmet therapeutic needs in PBC is the treatment of patients refractory to or intolerant of UDCA. It is of interest that the prevalence of chronic hepatitis B (CHB) in PBC patients was low in Taiwan and mainland China where the prevalence of CHB is very high. In this review, we overview this exciting and epoch-making symposium.
基金：
Health Labor Science Research Grants from Research on Measures for Intractable Diseases; Intractable Hepato-Biliary Diseases Study Group in Japan
第一作者单位：[1]Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan
通讯作者：
推荐引用方式(GB/T 7714)：
Tanaka Atsushi,Ma Xiong,Yokosuka Osamu,et al.Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016[J].HEPATOLOGY INTERNATIONAL.2016,10(6):909-915.doi:10.1007/s12072-016-9767-9.
APA：
Tanaka, Atsushi,Ma, Xiong,Yokosuka, Osamu,Weltman, Martin,You, Hong...&Takikawa, Hajime.(2016).Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.HEPATOLOGY INTERNATIONAL,10,(6)
MLA：
Tanaka, Atsushi,et al."Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016".HEPATOLOGY INTERNATIONAL 10..6(2016):909-915
医学